HC Wainwright Comments on Erasca’s Q1 Earnings (NASDAQ:ERAS)

Erasca, Inc. (NASDAQ:ERAS) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Erasca in a report issued on Thursday, November 13th. HC Wainwright analyst A. Maldonado expects that the company will earn ($0.11) per share for the quarter. The consensus estimate for Erasca’s current full-year earnings is ($0.73) per share.

Several other research firms have also commented on ERAS. Morgan Stanley reissued an “equal weight” rating and set a $2.00 price objective (down previously from $4.00) on shares of Erasca in a research note on Monday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research note on Wednesday, October 8th. Stifel Nicolaus set a $6.00 price target on Erasca in a research note on Thursday, November 6th. Bank of America restated an “underperform” rating and set a $1.00 price objective (down previously from $4.00) on shares of Erasca in a research report on Wednesday, September 3rd. Finally, Guggenheim increased their target price on Erasca from $3.00 to $5.00 and gave the company a “buy” rating in a research report on Friday. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $4.25.

Erasca Trading Up 1.6%

ERAS opened at $2.58 on Friday. The stock’s fifty day simple moving average is $2.18 and its 200 day simple moving average is $1.71. The stock has a market cap of $731.97 million, a PE ratio of -5.73 and a beta of 1.19. Erasca has a 1-year low of $1.01 and a 1-year high of $3.30.

Erasca (NASDAQ:ERAS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11).

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its stake in Erasca by 82.6% during the first quarter. Wellington Management Group LLP now owns 850,147 shares of the company’s stock worth $1,165,000 after purchasing an additional 384,475 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of Erasca by 20.1% in the 1st quarter. Deutsche Bank AG now owns 163,052 shares of the company’s stock worth $223,000 after acquiring an additional 27,282 shares during the period. Nuveen LLC bought a new stake in Erasca in the first quarter worth about $663,000. Frazier Life Sciences Management L.P. raised its position in shares of Erasca by 16.4% during the first quarter. Frazier Life Sciences Management L.P. now owns 22,575,851 shares of the company’s stock worth $30,929,000 after purchasing an additional 3,184,164 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of Erasca by 123.1% in the first quarter. XTX Topco Ltd now owns 123,501 shares of the company’s stock valued at $169,000 after purchasing an additional 68,140 shares in the last quarter. 67.78% of the stock is owned by institutional investors and hedge funds.

About Erasca

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.